Paper Details
- Home
- Paper Details
Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients.
Author: AdlerM, BrenardR, D'HeygereF, DelwaideJ, HenrionJ, HorsmansY, LangletP, LasserL, LaureysA, MichielsenP, MulkayJ P, NevensF, Van VlierbergheH
Original Abstract of the Article :
BACKGROUND: The combination therapy of pegylated-interferon-alpha2a plus ribavirin is considered as the standard of care for patients with chronic hepatitis C. A sustained viral response is obtained in 40-50% of naïve patients with genotype 1 and in around 80% of naïve patients with genotype 2 or 3....See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1111/j.1365-2036.2009.04052.x
データ提供：米国国立医学図書館（NLM）
Hepatitis C Treatment: A Quest for Improved Outcomes
Hepatitis C, a viral infection that can lead to serious liver disease, is a significant health concern worldwide. This research delves into the treatment of chronic hepatitis C, exploring the potential benefits of adding amantadine to the standard combination therapy of pegylated-interferon-alpha-2a plus ribavirin. The researchers conducted a randomized trial to assess the efficacy of this combination therapy with and without amantadine. The study found no significant improvement in treatment outcomes when amantadine was added to the standard regimen.
No Significant Advantage with Amantadine
The study found that amantadine did not significantly improve the effectiveness of the standard combination therapy for hepatitis C. This suggests that adding amantadine to the current regimen might not provide additional benefits for patients. It's like searching for a hidden oasis in the desert and finding only more sand dunes – amantadine did not offer the hoped-for improvement in treatment outcomes.
Navigating Hepatitis C Treatment
This research provides valuable insights into the ongoing quest for improved treatment options for hepatitis C. The study reminds us that the search for effective therapies is a continuous journey, and we must continue to explore new avenues to improve outcomes for patients. Just as a desert traveler navigates the terrain, so too must we navigate the complexities of hepatitis C treatment, seeking the most effective and safe approaches.
Dr.Camel's Conclusion
This study highlights the importance of rigorous clinical trials in evaluating new treatment strategies for hepatitis C. The findings suggest that amantadine does not offer a significant advantage when added to the standard combination therapy. Just as a camel adapts to the desert's harsh conditions, so too must we adapt our approach to medical treatments, constantly seeking new and improved solutions for our patients.
Date :
- Date Completed 2010-04-16
- Date Revised 2018-12-01
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.